The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.